RS3PE syndrome presenting as vascular endothelial growth factor associated disorder
Open Access
- 26 August 2005
- journal article
- other
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 64 (11), 1653-1655
- https://doi.org/10.1136/ard.2004.032995
Abstract
Objectives: To characterise serum concentrations of various cytokines and detection by magnetic resonance imaging (MRI) of synovial hypervascularity in patients with remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome before and after corticosteroid treatment. Methods: Vascular endothelial growth factor165 (VEGF165), tumour necrosis factor α (TNFα), and interleukin 1β (IL1β) were measured by enzyme linked immunosorbent assay (ELISA) in serum samples from three patients with RS3PE syndrome. As controls, serum samples from 26 healthy volunteers, 12 patients with rheumatoid arthritis, 10 patients with systemic lupus erythematosus, 13 patients with polymyositis/dermatomyositis, 13 patients with vasculitis syndrome, and 6 patients with mixed connective tissue disease were also analysed. Synovial hypervascularity of patients with RS3PE syndrome was estimated by rate of enhancement (E-rate) in a dynamic MRI study. Results: Serum concentrations of VEGF165 (mean (SD) 2223.3 (156.3) pg/ml) were significantly higher in patients with active RS3PE syndrome than in controls before corticosteroid treatment. TNFα and IL1β levels were similar in patients and controls. Synovial hypervascularity in affected joints and subcutaneous oedema decreased during corticosteroid treatment, in parallel with the fall in serum VEGF165. Conclusions: VEGF promotes synovial inflammation and vascular permeability in patients with RS3PE syndrome, suggesting that RS3PE can be classified as a VEGF associated disorder.Keywords
This publication has 10 references indexed in Scilit:
- Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremitiesClinical Rheumatology, 2004
- Pre‐administration of angiopoietin‐1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic modelThe Journal of Gene Medicine, 2003
- Molecular regulation of vessel maturationNature Medicine, 2003
- High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathiesClinical and Experimental Immunology, 2003
- Regulation of vascular permeability by vascular endothelial growth factorsVascular Pharmacology, 2002
- Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitisAnnals Of The Rheumatic Diseases, 2002
- Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosusLupus, 2002
- Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limbThe Lancet, 1996
- Remitting Seronegative Symmetrical Synovitis With Pitting EdemaJAMA, 1985
- Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites FluidScience, 1983